Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive OfficerBASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda Ramanayake as its new Chief Executive Officer.
Anaveon appoints Dieter Weinand as Chair of its Board of DirectorsBASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer Pharmaceuticals, as Chair of its Board of Directors. Martin Murphy, who served as Chair since 2019, has stepped down from the Board.
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical studyANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma- OMNIA-2 is a Phase I/II study evaluating ANV419 as monotherapy and in combination with daratumumab, or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma -
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanomaOMNIA-1 is a Phase I/II study to determine the efficacy of ANV419 as monotherapy and in combination with anti-PD1 or anti-CTLA4 antibodies in advanced melanoma
